Metastatic Ovarian Cancer
14
5
5
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.3%
2 terminated out of 14 trials
66.7%
-19.9% vs benchmark
7%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (14)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Measuring Oncological Value of Exercise and Statin
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer
[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian
EDMONd - Elemental Diet in Bowel Obstruction
TIL Therapy for Metastatic Ovarian Cancer